On January 21, 2021, Tyto Acquisition Corporation, a wholly owned subsidiary of Eli Lilly and Company, completed its tender offer for Prevail Therapeutics Inc. (PRVL). The subsequent merger was consummated before the open on January 22, 2021. As a result, each existing PRVL Common Share will be converted into the right to receive $22.50 net cash per share plus one non-transferable Contingent Value Right (CVR) per share.

NOTE: The CVR represents a non-transferable contractual right to receive an additional payment as described in the offer. PRVL options will not be adjusted to call for the delivery of the CVRs.

**CONTRACT ADJUSTMENT**

**DATE:** January 22, 2021

**NEW DELIVERABLE**

**PER CONTRACT:** $2,250.00 Cash ($22.50 x 100)

Settlement in PRVL options will take place through OCC’s cash settlement system. Settlement will be accomplished by payment of the difference between the extended strike amount and the cash deliverable.

**ACCELERATION OF EXPIRATIONS**

Pursuant to OCC Rule 807, equity stock option contracts whose deliverables are adjusted to call for cash-only delivery will be subject to an acceleration of the expiration dates for outstanding option series. (See OCC Information Memo 23707) Additionally, the exercise by exception (ex by ex) threshold for expiring series will be $.01 in all account types.

All series of Prevail Therapeutics Inc. options whose expiration dates are after 2-19-2021 will have their expiration dates advanced to 2-19-2021. Expiration dates occurring before 2-19-2021 (e.g., Flex options) will remain unchanged.

All Prevail Therapeutics Inc. options will utilize a $.01 exercise threshold.

Option Symbols: PRVL
Existing Expiration: All months
New expiration date: 2-19-2021
Existing American-style Prevail Therapeutics Inc. options remain exercisable at the option of the holder prior to their expiration. Exercised options will continue to settle in two business days.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.